Panobinostat Combination Therapy for Cholangiocarcinoma Treatment
Summary
The USPTO published patent application US20260091021A1 covering combination therapies comprising panobinostat for treating cholangiocarcinoma. The application (No. 19413668, filed December 9, 2025) names seven inventors and claims pharmaceutical compositions combining panobinostat with cytotoxic agents.
What changed
The USPTO published a patent application for combination therapies using panobinostat with cytotoxic agents to treat cholangiocarcinoma. The application claims pharmaceutical compositions and methods of treatment, with CPC classifications covering various therapeutic compound combinations including A61K 31/4045 (panobinostat) and multiple cytotoxic agent categories.
This is a published patent application creating no immediate compliance obligations. Inventors and patent practitioners should note the filing date of December 9, 2025 and publication date. Pharmaceutical researchers and drug developers may want to review freedom-to-operate implications for cholangiocarcinoma combination therapies.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA
Application US20260091021A1 Kind: A1 Apr 02, 2026
Inventors
Theresa AHRENS, Alexandra GADE, Eivind HOVIG, Jo KLAVENESS, Johannes LANDSKRON, Kjetil TASKEN, Tove Cecilie VIEBE
Abstract
The present invention relates to compositions and methods for treatment of cholangiocarcinoma and in particular to combination therapies comprising panobinostat compositions in combination with other cytotoxic agents, e.g. agents that potentiate the effects of panobinostat, for use in the treatment of cholangiocarcinoma. Pharmaceutical compositions comprising panobinostat and other cytotoxic agents are also provided.
CPC Classifications
A61K 31/4045 A61K 31/09 A61K 31/185 A61K 31/282 A61K 31/337 A61K 31/352 A61K 31/365 A61K 31/404 A61K 31/4545 A61K 31/4706 A61K 31/4745 A61K 31/506 A61K 31/517 A61K 31/519 A61K 31/5377 A61K 31/5517 A61K 31/704 A61K 33/243 A61P 35/00
Filing Date
2025-12-09
Application No.
19413668
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.